SBIR Phase I: Development of reliable pyrazinamide susceptibility testing at neutral pH

SBIR 第一阶段：开发中性 pH 值下可靠的吡嗪酰胺药敏测试

• 批准号: 2136133
• 负责人: Wanliang Shi
• 金额: $ 25.05万
• 依托单位: PZA INNOVATION LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-01-01 至 2023-10-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2136133&HistoricalAwards=false
• 关键词: SBIR; Phase; Development; reliable; pyrazinamide

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project aims to develop a new test for tuberculosis (TB). This technology will lead to more accurate and reliable results than the current standard of care. This project will improve TB treatment outcomes. Furthermore, it will combat the increasing incidence of multidrug-resistant TB by increasing the cure rate and reducing the spread of drug resistance. This Small Business Innovation Research (SBIR) Phase I project proposes to determine PZA susceptibility at neutral pH in reconstituted in vivo condition using the standard protocol of TB drug susceptibility testing. The current PZA susceptibility test is unreliable because it is performed in an acidic pH condition. An inappropriate inoculum size of M. tuberculosis may neutralize the pH of the medium or fail to grow due to growth inhibition at the acidic pH condition. This leads to frequent false results, leading to improper treatment. The proposed research will advance a novel approach, determining phenotypic PZA susceptibility at neutral pH in a proprietary culture media. This project will optimize the media for PZA susceptibility testing, and the susceptibility testing will be implemented using the standard protocol of TB drug susceptibility testing with reliability and accuracy. Together, this studies will not only establish a reliable PZA susceptibility testing, but also combine all TB drug susceptibilities in one effective system.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I期项目的更广泛的影响/商业潜力旨在开发新的结核病测试（TB）。与当前的护理标准相比，这项技术将带来更准确和可靠的结果。该项目将改善结核病治疗结果。此外，它将通过提高治愈率并减少耐药性的扩散来打击多种耐药性结核病的发生率的增加。 这项小型企业创新研究（SBIR）I阶段项目提议使用TB药物易感性测试的标准协议在重构的体内条件下确定中性pH值的PZA敏感性。当前的PZA敏感性测试是不可靠的，因为它是在酸性pH条件下进行的。结核分枝杆菌的不适当的直膜大小可能中和培养基的pH值或由于酸性pH条件下的抑制作用而无法生长。这导致经常出现错误的结果，导致治疗不当。拟议的研究将推进一种新的方法，确定专有培养基中中性pH的表型PZA敏感性。该项目将对PZA易感性测试优化介质，并且将使用具有可靠性和准确性的TB药物敏感性测试的标准方案来实施敏感性测试。这项研究不仅将建立可靠的PZA易感性测试，而且还将所有结核病药物敏感性结合在一个有效的系统中。该奖项反映了NSF的法定任务，并被认为是通过基金会的智力优点和更广泛影响的审查标准通过评估来通过评估来支持的。